Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo
Gilead Sciences stock was down roughly 2% on Friday alongside an FDA update concerning HIV drug Bixlenvo.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 3,480,444 | $439,719,295 | -13% | 0.05% |
| 2. | Holocene Advisors Brandon Haley | 3,216,892 | $406,422,135 | +24% | 0.92% |
| 3. | D E Shaw D. E. Shaw | 2,294,789 | $289,923,642 | +1043% | 0.14% |
| 4. | Renaissance Technologies Jim Simons | 2,217,376 | $280,143,284 | +4% | 0.39% |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 1,823,224 | $230,346,120 | +785% | 0.25% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | $999,150.00 | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | $430,493.00 | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | $439,955.00 | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | $335,974.40 | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | $158,064.64 | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $148.82 | 6,880 | $1,023,900.18 | 12,894 | 2026-08-26 | Filing | |
| $148.24 | 3,402 | $504,296.49 | 19,774 | 2026-08-26 | Filing | |
| $148.82 | 4,600 | $684,590.40 | 12,894 | 2026-08-26 | Filing | |
| $148.31 | 3,118 | $462,432.45 | 17,494 | 2026-08-26 | Filing | |
| $146.26 | 335 | $48,997.10 | 10,066 | 2026-08-20 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 121,844,108 | $15,393,784,619 | 0.23% | |
| 2. | 81,091,734 | $10,245,129,674 | 0.22% | |
| 3. | 66,870,816 | $8,448,459,045 | 0.37% | |
| 4. | 61,216,552 | $7,734,099,180 | 0.23% | |
| 5. | 40,988,975 | $5,178,544,683 | 0.61% |
News See All
Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?
Gilead Sciences, Inc. (NASDAQ:GILD) produced an unusual earnings report in fiscal Q2 2026.
Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise?
Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to approximately $7.8 billion.
Gilead’s Revenue Is Accelerating, But are its Acquisitions Worth the Cost?
Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease.
Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?
The next few years will test whether Pfizer Inc. (NYSE:PFE) can replace yesterday’s blockbusters, and whether Gilead Sciences, Inc. (NASDAQ:GILD) can become more than an HIV company.
Tempus AI Stock (TEM) Is Surging 24% on Wednesday – Here’s Why
Tempus AI ($TEM) surged nearly 24% on Wednesday after a major Phase 3 cancer vaccine update from Merck ($MRK) and Moderna ($MRNA). The news instant...
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
On August 11, Gilead Sciences, Inc. (NASDAQ:GILD) exercised its option to exclusively license a preclinical bispecific program targeting solid tumors using MacroGenics, Inc.
Could Merck & Co., Inc. (MRK) and Gilead Sciences, Inc. (GILD)’s Partnership Create the Next Big Pharma Growth Engine
Two biopharma giants, Merck & Co., Inc. (NYSE:MRK) and Gilead Sciences, Inc.
Options Volatility and Implied Earnings Moves Today, August 04, 2026
Today, several major companies are expected to report earnings: Advanced Micro Devices (AMD), Caterpillar (CAT), Energy Transfer (ET), Gilead Scien...
Could Gilead Sciences (GILD) Have a Major HIV Growth Engine in Yeztugo?
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here.
Hedge Fund Resource Center